Antithymocyte Globulin (ATG) Injection, derived from rabbit antibodies, is a crucial immunosuppressant used to prevent and treat kidney transplant rejection. By suppressing the immune response, it enhances the success of kidney transplantation, ensuring improved outcomes for patients undergoing this critical procedure. ATG plays a pivotal role in creating a conducive environment for successful kidney transplants, contributing to the overall success and well-being of transplant recipients.